BidaskClub upgraded shares of Emergent Biosolutions, Inc. (NYSE:EBS) from a hold rating to a buy rating in a report published on Friday.

Separately, Zacks Investment Research downgraded Emergent Biosolutions from a buy rating to a hold rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Emergent Biosolutions has an average rating of Buy and an average target price of $44.00.

Emergent Biosolutions (EBS) opened at 35.81 on Friday. Emergent Biosolutions has a 12 month low of $24.47 and a 12 month high of $36.95. The company has a market cap of $1.48 billion, a PE ratio of 22.81 and a beta of 1.22. The company has a 50 day moving average price of $35.27 and a 200-day moving average price of $31.88.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million during the quarter, compared to analysts’ expectations of $111.57 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. Emergent Biosolutions’s revenue was up 10.4% on a year-over-year basis. Equities analysts predict that Emergent Biosolutions will post $1.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://theolympiareport.com/2017/08/28/emergent-biosolutions-inc-ebs-upgraded-at-bidaskclub.html.

In related news, Director Jerome M. Hauer sold 10,776 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total value of $386,104.08. Following the sale, the director now directly owns 29,421 shares in the company, valued at $1,054,154.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Fuad El-Hibri sold 25,000 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $36.50, for a total value of $912,500.00. Following the completion of the sale, the chairman now owns 1,630,216 shares in the company, valued at $59,502,884. The disclosure for this sale can be found here. Insiders sold 60,776 shares of company stock worth $2,186,104 over the last 90 days. Company insiders own 16.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Comerica Bank increased its stake in Emergent Biosolutions by 1.3% in the first quarter. Comerica Bank now owns 61,721 shares of the biopharmaceutical company’s stock worth $1,871,000 after buying an additional 800 shares in the last quarter. US Bancorp DE increased its stake in Emergent Biosolutions by 12.0% in the first quarter. US Bancorp DE now owns 40,985 shares of the biopharmaceutical company’s stock worth $1,191,000 after buying an additional 4,398 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Emergent Biosolutions by 213.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 67,106 shares of the biopharmaceutical company’s stock worth $1,949,000 after buying an additional 45,688 shares in the last quarter. LSV Asset Management increased its stake in Emergent Biosolutions by 14.4% in the first quarter. LSV Asset Management now owns 622,715 shares of the biopharmaceutical company’s stock worth $18,083,000 after buying an additional 78,500 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in Emergent Biosolutions by 5.9% in the first quarter. Great West Life Assurance Co. Can now owns 47,682 shares of the biopharmaceutical company’s stock worth $1,384,000 after buying an additional 2,649 shares in the last quarter. Institutional investors own 85.44% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.